Comparative Pharmacology
Head-to-head clinical analysis: ADZENYS ER versus ADZENYS XR ODT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADZENYS ER versus ADZENYS XR ODT.
ADZENYS ER vs ADZENYS XR-ODT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ADZENYS ER is a central nervous system (CNS) stimulant that blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their concentrations in the synaptic cleft.
Adzenys XR-ODT contains amphetamine, a central nervous system stimulant that increases extracellular levels of dopamine and norepinephrine by inhibiting their reuptake and promoting their release from presynaptic terminals.
Adults: Initial 5-10 mg orally once daily; titrate in 5-10 mg increments weekly to optimal response; max 60 mg/day.
Initial: 9.4 mg orally once daily in the morning; titrate in increments of 9.4 mg per week based on tolerability and response. Maximum: 56.4 mg once daily.
None Documented
None Documented
6-8 hours in adults; in children 3-6 hours, requiring twice-daily dosing for sustained effect
Approximately 9-14 hours in adults, 8-11 hours in children (6-12 years). Extended-release pharmacokinetics produce a longer clinical duration compared to immediate-release formulations.
70% renal (30% unchanged, 40% as metabolites), 30% fecal/biliary
Renal: approximately 90% as unchanged drug and metabolites (30%-40% as amphetamine, 40%-50% as hippuric acid and benzoic acid). Fecal: <4%. Biliary: negligible.
Category C
Category C
CNS Stimulant
CNS Stimulant